Discussion: Women’s and Men’s Health, Infectious Disease, and Hematologic Disorders

Learning Resources

Required Readings (click to expand/reduce)

Rosenthal, L. D., & Burchum, J. R. (2018). Lehne’s pharmacotherapeutics for advanced practice providers. St. Louis, MO: Elsevier.

· Chapter 68, “Basic Principles of Antimicrobial Therapy” (pp. 769–781)

· Chapter 69, “Drugs That Weaken the Bacterial Cell Wall I: Penicillins” (pp. 783–790)

· Chapter 73, “Sulfonamides and Trimethoprim” (pp. 619–826)

· Chapter 74, “Drug Therapy of Urinary Tract Infections” (pp. 827–831)

· Chapter 75, “Antimycobacterial Agents” (pp. 833–847)

· Chapter 76, “Miscellaneous Antibacterial Drugs” (pp. 849–853)

· Chapter 77, “Antifungal Agents” (pp. 855–866)

· Chapter 78, “Antiviral Agents I: Drugs for Non-HIV Viral Infections” (pp. 867–886)

· Chapter 80, “Drug Therapy of Sexually Transmitted Diseases” (pp. 905–911)

Montaner, J. S. G., Lima, V. D., Harrigan, P. R., Lourenço, L., Yip, B., Nosyk, B., … Kendall, P. (2014). Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: The “HIV Treatment as Prevention” experience in a Canadian setting. PLoS ONE, 9(2), e87872. Retrieved from https://doi.org/10.1371/journal.pone.0087872

 

This study examines HAART therapy and its sustainability and profound population-level decrease in morbidity, mortality, and HIV transmission.